| 王欣欣,黄松洁,于 洋,周琳艳,陈美珺.血清ProGRP、SCCAg及HE4与非小细胞肺癌患者病理特征的关系及其诊断价值分析[J].,2020,(13):2497-2501 |
| 血清ProGRP、SCCAg及HE4与非小细胞肺癌患者病理特征的关系及其诊断价值分析 |
| The Relationship between Serum ProGRP, SCCAg and HE4 and the Pathological Characteristics of Non-small Cell Lung Cancer and Its Diagnostic Value |
| 投稿时间：2020-02-19 修订日期：2020-03-13 |
| DOI：10.13241/j.cnki.pmb.2020.13.020 |
| 中文关键词: 胃泌素释放肽前体 鳞状上皮细胞癌抗原 人附睾蛋白4 非小细胞肺癌 病理特征 诊断价值 |
| 英文关键词: Progastrin-releasing peptide Squamous cell carcinoma antigen Human epididymis protein-4 Non-small cell lung cancer Clinicopathological parameters Diagnostic value |
| 基金项目:福建省科技计划资助项目(2017J02791) |
|
| 摘要点击次数: 712 |
| 全文下载次数: 331 |
| 中文摘要: |
| 摘要 目的：探讨血清胃泌素释放肽前体（ProGRP）、鳞状上皮细胞癌抗原（SCCAg）、人附睾蛋白4 （HE4）水平与非小细胞肺癌（NSCLC）患者病理特征的关系，分析其对NSCLC的临床诊断价值。方法：选择2015年9月至2020年2月我院接诊的110例NSCLC患者（观察组）和100例健康志愿者（对照组）为研究对象，检测血清ProGRP、SCCAg、HE4水平。分析血清ProGRP、SCCAg、HE4水平与NSCLC患者临床病理特征的关系。采用受试者工作特征（ROC）曲线分析血清ProGRP、SCCAg、HE4诊断NSCLC的价值。结果：观察组血清ProGRP、SCCAg、HE4水平均高于对照组（P＜0.05），低中分化、TNM Ⅲ~Ⅳ期、淋巴结转移患者血清ProGRP、SCCAg 水平分别高于高分化、TNM Ⅰ~Ⅱ期、无淋巴结转移患者（P＜0.05）；TNM 分期Ⅲ~Ⅳ期、淋巴结转移患者血清HE4水平分别高于TNM Ⅰ~Ⅱ期、无淋巴结转移患者（P＜0.05）。ROC曲线分析结果显示ProGRP、SCCAg、HE4、ProGRP+SCCAg+HE4诊断NSCLC的曲线下面积（AUC）分别为0.834（95%CI：0.779～0.888）、0.584（95%CI：0.507～0.662）、0.743（95%CI：0.675～0.811）、0.947（95%CI：0.910～0.984）。结论：NSCLC患者血清ProGRP、SCCAg、HE4水平明显升高，血清ProGRP、SCCAg水平与NSCLC患者分化程度、TNM分期和淋巴结转移有关，血清HE4水平与TNM分期和淋巴结转移有关。联合检测ProGRP、SCCAg、HE4对NSCLC诊断具有较高价值，可提高早期诊断准确性。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between the levels of serum gastrin releasing peptide precursor (ProGRP), squamous cell carcinoma antigen(SccAg), human epididymal protein 4(HE4) and the pathologicalcharacteristics of patients with non-small cell lung cancer (NSCLC), and analyze its clinical diagnostic value for NSCLC. Methods: From September 2015 to February 2020, 110 patients with NSCLC (observation group) and 100 healthy volunteers (control group) who were received by our hospital were selected as the study subjects, and the serum ProGRP, SCCAg and HE4 levels were measured. The relationship between serum ProGRP, SCCAg, HE4 levels and clinicopathological parameters of patients with NSCLC were analyzed. Receiver operator characteristics curve (ROC) was used to analyze the value of ProGRP, SCCAg, HE4 and ProGRP, SCCAg, HE4 in the diagnosis of NSCLC. Results: The levels of ProGRP, SCCAg and HE4 in observation group were higher than those in control group (P<0.05). The serum ProGRP and SCCAg levels of patients with NSCLC with low and middle differentiation, TNM Ⅲ-Ⅳ staging and lymph node metastasis were higher than those of patients with NSCLC with high differentiation, TNM Ⅰ-Ⅱ staging and no lymph node metastasis (P<0.05). The serum HE4 levels of TNM Ⅲ-Ⅳ staging and lymph node metastasis were higher than those of TNM Ⅰ-Ⅱ and no lymph node metastasis (P<0.05). ROC analysis showed that the AUC of ProGRP, SCCAg, HE4, ProGRP + SCCAg + HE4 combined diagnosis of NSCLC was 0.834（95%CI: 0.779～0.888）, 0.584（95%CI: 0.507～0.662）, 0.743（95%CI: 0.675～0.811）, 0.947（95%CI: 0.910～0.984） respectively. Conclusion: The levels of ProGRP, SCCAg and HE4 in patients with NSCLC are significantly increased, levels of serum ProGRP and SCCAg are related to the degree of NSCLC differentiation, TNM staging and lymph node metastasis. Serum HE 4 levels are related to TNM stage and lymph node metastasis. The combined detection of ProGRP, SCCAg and HE4 is of high value for NSCLC diagnosis and can improve the accuracy of early diagnosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
